Manufacturer record
Mapro Pharmaceuticals Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by Mapro Pharmaceuticals Pvt. Ltd (Gujarat) was declared Not of Standard Quality in February 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: CD-11449, Cyra-D (Rabeprazole Sodium & Domperidone Capsules) (exp Sep 2023). CDL Kolkata (CDSCO lab) found it not of standard quality: Dissolution of Domperidone & Assay of Rabeprazole Sodium & Domperidone. Listed in the February 2023 alert.
Records by type
1 record linked to Mapro Pharmaceuticals Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cyra-D (Rabeprazole Sodium & Domperidone Capsules) | Batch CD-11449Mfg Oct 2021 · Exp Sep 2023 | Dissolution of Domperidone & Assay of Rabeprazole Sodium & DomperidoneAssay | CDL KolkataCDSCO lab | Feb 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.